This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI’s library.

November 2008

GP15-A3

Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline—Third Edition

This document discusses procedures for cervicovaginal specimen collection, as well as the preparation, fixation, staining, and storage of Papanicolaou-stained cervicovaginal cytology slides.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute  
*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

**Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

**Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

**Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

**Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
www.clsi.org  
standard@clsi.org
Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline—Third Edition

Volume 28 Number 28

George Birdsong, MD
Mujtaba Husain, MD
Tremel Faison, SCT(ASCP)
Daron G. Ferris, MD
Barbara Fetterman, SCT(ASCP)
Lisa C. Flowers, MD, FACOG
Maria A. Friedlander, MPA, CT(ASCP)
MariBeth Gagnon, MS, CT(ASCP), HTL
Leza N. Gallo, MD
Gabriele Medley, AM, MB, BS, FRCPA, FIAC

Abstract

Clinical and Laboratory Standards Institute document GP15-A3—Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline—Third Edition is intended for health care providers who are responsible for collecting cervicovaginal cytology specimens and preparing conventional Papanicolaou smears and liquid-based preparations. The guideline focuses on quality collection and processing of specimens, addressing all steps, including patient assessment, test requisition, specimen collection, specimen transport, and specimen receipt and processing. Illustrations of the techniques are described, and a specimen requisition form is also included.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org
Copyright ©2008 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

**Suggested Citation**


**Previous Editions:**

**Reaffirmed:**
March 2016

**Archived:**
September 2016

ISBN 1-56238-679-4
ISSN 0273-3099
Contents

Abstract.................................................................................................................................................... i

Committee Membership........................................................................................................................ iii

Foreword.............................................................................................................................................. vii

1 Scope.......................................................................................................................................... 1

2 Introduction................................................................................................................................ 1

3 Standard Precautions.................................................................................................................. 1

4 Terminology............................................................................................................................... 1

4.1 Definitions........................................................................................................................... 1

4.2 Abbreviations/Acronyms.............................................................................................. 3

5 Education................................................................................................................................... 3

5.1 Educating the Patient.................................................................................................... 3

5.2 Educating the Physician/Provider................................................................................. 4

6 Test Requisition ......................................................................................................................... 4

6.1 Demographic Information............................................................................................. 4

6.2 Clinical Information...................................................................................................... 4

6.3 Design........................................................................................................................... 5

6.4 Electronic Medical Records.......................................................................................... 7

7 Specimen Collection .................................................................................................................. 7

7.1 Position of the Patient................................................................................................... 7

7.2 Preparation of the Cervix.............................................................................................. 7

7.3 Specimen Collection Procedure.................................................................................. 10

8 Slide/Specimen Fixation .......................................................................................................... 13

8.1 Types of Fixatives....................................................................................................... 14

9 Specimen Transport ............................................................................................................ ..... 15

9.1 Conventional Smear.................................................................................................... 15

9.2 Liquid-Based Specimen.............................................................................................. 15

10 Specimen Receipt............................................................................................................... ...... 15

10.1 Criteria for Specimen Rejection .................................................................................. 15

10.2 Specimen Accession ................................................................................................... 16

11 Specimen Processing and Staining .......................................................................................... 16

11.1 Process ........................................................................................................................ 16

11.2 Clearing....................................................................................................................... 20

11.3 Reagent Use and Maintenance................................................................................. 20

11.4 Mounting..................................................................................................................... 24

12 Specimen Storage............................................................................................................... ...... 25

13 Ancillary Studies...................................................................................................................... 25
Contents (Continued)

14  Results Reporting ..................................................................................................................... 26
15  Record Retention ..................................................................................................................... 26
16  Procedure Manual .................................................................................................................... 26

References ............................................................................................................................................. 28

Additional References ........................................................................................................................... 30

Summary of Consensus Comments and Working Group Responses ................................................... 31
Summary of Delegate Comments and Working Group Responses ...................................................... 32
The Quality Management System Approach ........................................................................................ 36
Related CLSI Reference Materials ........................................................................................................ 37
Foreword

Dr. George N. Papanicolaou developed cervicovaginal cytology to facilitate the detection of precancerous lesions of the uterine cervix during the routine screening procedure for female patients. Regularly scheduled cervical screening is recognized as the most effective method of reducing the incidence and mortality of cervical cancer.

For cervicovaginal cytology to produce optimal results, the specimen collection procedure must be carried out by a health care provider on an adequately prepared and informed patient. Specimens should be evaluated using quality-controlled laboratory techniques.

This third edition has been updated to provide additional information on education of the patient, design of the requisition, and specimen collection. Additional information regarding the handling and processing of liquid-based Pap tests and ancillary studies is also provided. The nomenclature of the second edition of The Bethesda System is incorporated in this edition, and handling of cases in the context of an electronic health record is discussed.

Key Words

Cervical cancer, cervical cancer screening, cervicovaginal specimen collection, diagnostic cervicovaginal cytology, human papillomavirus (HPV), liquid-based preparations, Pap test, Papanicolaou stain, Papanicolaou technique, precancerous lesions
Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline—Third Edition

1 Scope

This guideline provides the most current recommendations regarding standard precautions, patient assessment, test requisition, cervicovaginal specimen collection, specimen transport, specimen receipt, specimen processing, and storage of slides. Cytologic interpretation is outside the scope of this document and is not addressed.

This guideline is useful to health care providers, laboratory directors, supervisors, and others who have responsibilities for quality control in cytopathology laboratories.

2 Introduction

The primary purpose of obtaining a sample of cells from the uterine cervix is to detect precancerous lesions and/or cervical cancer. The goal of this guideline is to provide recommendations for optimal specimen collection and processing. This is essential for accurate cytologic interpretation.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major feature of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention. For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.

4 Terminology

4.1 Definitions

colposcopy— a procedure where a dissecting-type microscope is used to view the cervix following an application of dilute acetic acid, which colors the cervical intraepithelial neoplasia (CIN) lesions transiently white (acetowhite) and/or accentuates abnormal vasculature to facilitate the identification of intraepithelial lesions and cancer for biopsy; NOTE 1: Colposcopy is done following an abnormal Pap test result, or in the investigation of symptoms of cervical pathology such as abnormal vaginal bleeding, even if the Pap test is reported as normal. Colposcopy allows illuminated examination of the lower genital tract to detect epithelial abnormalities and assess severity of these lesions; NOTE 2: Colposcopy is also done when the cervix is visually abnormal in appearance, and when a high-risk (HR) HPV test is positive in the following clinical situations: 1) postcolposcopy follow-up of women treated for CIN 2,3; 2) postcolposcopy follow-up of women not found to have CIN 2,3 or adenocarcinoma in situ (AIS) at initial colposcopy and referred for the evaluation of repeat atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells—cannot exclude high-grade squamous intraepithelial lesion (ASC-H), low-grade squamous intraepithelial lesion (LSIL), and atypical glandular cells not otherwise specified (AGC-NOS); and 3) follow-up of women age 30 and over having a normal Pap and a positive HR HPV
test on the initial screen, and either a positive HR HPV test and/or an abnormal Pap on the 12-month follow-up exam.

**conventional smear** – a method of slide preparation where a sample of cells collected from the cervix/vagina is smeared and fixed onto a glass slide in the patient examination room.

**diethylstilbestrol (DES)** – synthetic, nonsteroidal estrogens administered during the last century to gravid women at risk for early pregnancy loss; **NOTE:** There is evidence that administration may have caused adenosis (non-neoplastic) and clear cell adenocarcinoma (neoplastic) in the female genital (cervix and vagina) tract of some of the daughters who were exposed in utero.

**dysplasia** – precancerous cellular changes in the cervix that include a spectrum of cellular abnormalities, described as mild, moderate, and severe or marked dysplasia; **NOTE:** Dysplasia terminology has been replaced with Bethesda terminology for Pap tests; however, it is still used for histologic specimens in many laboratories.

**epithelial cell abnormalities** – precancerous cellular changes in the cervix that include a spectrum of cellular abnormalities such as atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells—cannot exclude high-grade squamous intraepithelial lesion (ASC-H), atypical glandular cells (AGC), low-grade squamous intraepithelial lesion (LSIL), koilocytosis, HPV effect, and high-grade squamous intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS), and all varieties of epithelial neoplasms; **NOTE:** These terms are part of the Bethesda 2001 System nomenclature. The Bethesda System is in current use in the United States and several other countries.

**human papillomavirus (HPV)** – the most common sexually transmitted virus and causative agent in the pathogenesis of cervical cancer and its precursor lesions in almost all cases.

**intraepithelial lesion** – Bethesda System terminology for a subgroup of epithelial cell abnormalities that include low-grade squamous intraepithelial lesion (LSIL), koilocytosis, HPV effect, and high-grade squamous intraepithelial lesion (HSIL); **NOTE:** ASC-US, ASC-H, AGC, invasive carcinomas, sarcomas, and other neoplasms are not included among intraepithelial lesions.

**liquid-based Pap preparations** – a method of slide preparation where a sample of cells from the cervix/vagina is collected and rinsed into a vial of preservative fluid in the patient examination room, then transported to the laboratory where an automated processing device produces a thin layer of evenly distributed cervicovaginal cells onto a glass slide.

**original squamocolumnar junction (OSCJ)** – the junction between the squamous and columnar epithelium at birth.

**Pap test** – a sample of cells collected from the cervix (or vaginal cuff in posthysterectomy patients), prepared by conventional or liquid-based methods, and stained using the Papanicolaou staining technique for the purpose of screening for cervical cancer and precancerous lesions of the cervix and vagina.

**Papanicolaou stain technique** – a method of polychromatic staining developed by George N. Papanicolaou to identify differences in cellular morphology, maturity, and metabolic activity.

**precursor lesions** – precancerous changes in the cervical/vaginal epithelium.

**squamocolumnar junction (SCJ)** – the current junction between the squamous and columnar epithelium.
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI/NCCLS document HS1—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Documents & Records
- Organization
- Personnel
- Equipment
- Purchasing & Inventory
- Information Management
- Process Control
- Occurrence Management
- Assessments—External & Internal
- Customer Service
- Facilities & Safety

GP15-A3 addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI/NCCLS document GP26—Application of a Quality Management System Model for Laboratory Services defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

GP15-A3 addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Adapted from CLSI/NCCLS document HS01—A Quality Management System Model for Health Care.

<table>
<thead>
<tr>
<th>Preexamination</th>
<th>Examination</th>
<th>Postexamination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination ordering</td>
<td>Sample collection</td>
<td>Sample transport</td>
</tr>
<tr>
<td>X</td>
<td>X MM03</td>
<td>X MM03</td>
</tr>
</tbody>
</table>

Adapted from CLSI/NCCLS document HS01—A Quality Management System Model for Health Care.
Related CLSI Reference Materials∗

**GP02-A5** Laboratory Documents: Development and Control; Approved Guideline—Fifth Edition (2006). This document provides guidance on development, review, approval, management, and use of policy, process, and procedure documents in the medical laboratory community.

**M29-A3** Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

**MM03-A2** Molecular Diagnostic Methods for Infectious Diseases; Approved Guideline—Second Edition (2006). This guideline addresses topics relating to clinical applications, amplified and nonamplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors, and interfering substances, controlling false-positive reactions, reporting and interpretation of results, quality assurance, regulatory issues, and recommendations for manufacturers and clinical laboratories.

* Proposed-level documents are being advanced through the Clinical and Laboratory Standards Institute consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.